The Patent Finder

Celularity, Inc.

3 patents currently held · Updated Nov 15, 2026
34 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Dec 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jun 1, 2027
    The maintenance fee for Amnion Derived Adherent Cells (US 9,198,938) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 7 terms have ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 3 of 3

PatentTitleStatus Expires Confidence
US 9,198,938Amnion Derived Adherent Cells
In force
 · High confidence
In forceHigh confidence
US 10,179,152Therapy with Cells from Human Placenta and Hematopoietic Cells
In force
 · High confidence
In forceHigh confidence
US 10,659,835Streaming Media Presentation System
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 3: 34 patents in force now held by others · 32 lapsed for an unpaid fee · 37 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 pending · 37 abandoned · 18 no status recorded

Showing 1 to 10 of 61, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/205,303Jun 2, 2023No status recorded
18/201,907May 25, 2023No status recorded
18/728,298Cleavage Resistant CD16 Constructs and Uses ThereofJan 11, 2023Pending
18/057,487Nov 21, 2022Abandoned
18/056,088Natural Killer Cells and ILC3 Cells and Uses ThereofNov 16, 2022Abandoned
18/048,291Enhanced Placental Stem Cells and Uses ThereofOct 20, 2022Abandoned
18/293,243Placenta-Dervied NK Cells as a Senol Ytic for Therapeutic and Other UsesJul 29, 2022Pending
17/733,321Apr 29, 2022Abandoned
18/555,412Multi-Layer Amniotic Tissue Grafts and Uses ThereofApr 13, 2022Abandoned
17/645,004Genetically Modified Natural Killer CellsDec 17, 2021Abandoned
10 of 61 applications shown.
Pro members see all 61 published applications.
Pro members: see all 61 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited